Utilization of targeted disease-modifying anti-rheumatic drugs (DMARDs) for managing rheumatoid arthritis in the last decade: A two-country comparison
Date
2021
Authors
Park, S.H.
Jeon, H.L.
Kim, S.C.
Hillen, J.
Gadzhanova, S.
Shin, J.Y.
Pratt, N.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
International Journal of Clinical Pharmacology and Therapeutics, 2021; 59(10):639-644
Statement of Responsibility
Conference Name
DOI
Abstract
<h4>Objective</h4>To compare trends in the use of targeted disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis (RA), between Korea and Australia.<h4>Materials and methods</h4>Using sampled claims databases in Korea and Australia (2010 - 2018), we analyzed the trends in the use of individual targeted DMARDs (biologic and targeted synthetic) for RA in both countries.<h4>Results</h4>The use of targeted DMARDs for the management of RA showed an increase of over 200 and 300% in Australia and Korea, respectively. The tumor necrosis factor inhibitors (TNFis) etanercept and adalimumab were the most commonly prescribed drugs in 2010 in both countries, with non-TNFi use increasing over the study period. The introduction of tofacitinib in 2015 led to 10 and 15% market share uptake in Korea and Australia, respectively.<h4>Conclusion</h4>Trends in the use of targeted DMARDs for RA were similar in Korea and Australia, and the use of non-TNFis, including tofacitinib, increased in both countries.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Copyright 2021